Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: acalabrutinib
Drug: rituximab (IV)
Drug: Lenalidomide

First Posted Date: 2014-07-03

Last Posted Date: 2024-07-11

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 113

Registration Number: NCT02180711

Locations: 🇮🇹
Research Site, Palermo, Italy

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Electrocardiogram
Drug: Ibrutinib
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Biological: Rituximab

First Posted Date: 2014-06-10

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT02160015

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-06-09

Last Posted Date: 2019-07-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT02159365

Locations: 🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States
🇺🇸
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States

and more 26 locations

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase 3

Withdrawn

Conditions: Multiple Myeloma
Neoplasms
Plasma Cells
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Therapeutic Uses

Interventions: Drug: Lenalidomide

First Posted Date: 2014-06-04

Last Posted Date: 2018-04-10

Lead Sponsor: Celgene

Registration Number: NCT02155634

Treatment Optimization in Patients With Untreated Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Placebo

First Posted Date: 2014-05-23

Last Posted Date: 2019-01-16

Lead Sponsor: Dr. med. Lars-Olof Muegge

Target Recruit Count: 85

Registration Number: NCT02145598

Locations: 🇩🇪
Onkologische Schwerpunktpraxis, Dresden, Germany
🇩🇪
Charité - Campus Benjamin Franklin Medizinische Klinik II, Berlin, Germany
🇩🇪
Universitätsklinikum Jena, Klinik für Innere Medizin II, Abt. Hämatologie und internistische Onkologie, Jena, Germany

and more 16 locations

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma Relapsed
Diffuse Large B Cell Lymphoma Refractory

Interventions: Drug: Ibrutinib
Drug: DA-EPOCH-R
Drug: Lenalidomide

First Posted Date: 2014-05-20

Last Posted Date: 2019-02-05

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 35

Registration Number: NCT02142049

Locations: 🇺🇸
SITE-1, Duarte, California, United States
🇺🇸
SITE-10, Orange, California, United States
🇺🇸
SITE-6, Bethesda, Maryland, United States

and more 7 locations

Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

Phase 3

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2014-05-01

Last Posted Date: 2021-04-13

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 250

Registration Number: NCT02128061

Locations: 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
ZNA Stuivenberg, Antwerpen, Belgium
🇧🇪
CHR Citadelle, Liege, Belgium

and more 94 locations

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Phase 2

Completed

Conditions: Alkylating Agent-Related Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2014-04-30

Last Posted Date: 2022-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT02126553

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2014-04-11

Last Posted Date: 2021-04-14

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT02112175

Locations: 🇫🇷
CHRU Hopital Claude Huriez, Lile Cedax, France
🇫🇷
Hopital Saint Louis, Paris, France
🇫🇷
CH Argenteuil Victor DupouyHematologie, Argenteuil, France

and more 70 locations

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Sonidegib

First Posted Date: 2014-03-13

Last Posted Date: 2021-12-03

Lead Sponsor: Mayo Clinic

Target Recruit Count: 28

Registration Number: NCT02086552

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy